CellProthera
Mulhouse
About CellProthera
CellProthera is the first company having conducted successful proof of principle study with autologous CD34+ stem cells to repair myocardial tissue after acute myocardial infarct (AMI). The clinical outcome indicated an excellent safety profile associated with outstanding clinical benefits. The innovative approach developed by CellProthera is viewed by experts as one of the most effective to treat AMI and prevent secondary congestive heart failure (CHF).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $9.1M
- Last round: Series Unknown (Feb 2017)
- Website: cellprothera.com
- Phone: +33369719771
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/cellprothera-74170 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.